https://www.selleckchem.com/products/vu661013.html
19 to 0.73, p0.016) within 2 years of follow-up. Subgroup analysis of MACE individual components showed that BP-DES were associated with lower cardiac deaths (HR 0.35; 95% CI 0.18 to 0.94; p0.001) compared to DP-DES, but not recurrent myocardial infarction and total repeat revascularisation. BP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STEMI undergoing PPCI. BP-DES were associated with better clinical outcomes compared to second-generation DP-DES in patients with STE